Clinical trials · Pennsylvania
Pancreatic Adenocarcinoma clinical trials in Pennsylvania
We’re tracking 40 recruiting pancreatic adenocarcinoma studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06998940RecruitingPhase 3
Chemotherapy with or without panitumumab for pancreatic cancer
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
Chadds Ford, PennsylvaniaAges 18 years+ - NCT06896188RecruitingPhase 1
Study of 9-ING-41 and retifanlimab plus chemo for advanced pancreatic cancer
This trial tests a new combination of two experimental drugs (9-ING-41 and retifanlimab) plus a standard chemotherapy regimen (modified FOLFIRINOX) for people with advanced or metastatic pancreatic cancer who have not yet received treatment for their advanced disease. The goal is to see if this combination is safe and effective.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06048484RecruitingPhase 2
Combination therapy for localized pancreatic cancer
This trial tests a combination of drugs for people with localized pancreatic cancer who have already completed 8 cycles of modified FOLFIRINOX chemotherapy before surgery. The goal is to see if adding these drugs after chemo and radiation helps improve outcomes.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07450859RecruitingPhase 2
Study of new drug for metastatic pancreatic cancer
This trial tests a new drug called nuzefatide pevedotin for people with metastatic pancreatic cancer that has progressed after one prior treatment. The drug targets a protein called EphA2 found on some tumor cells and may slow tumor growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07217717RecruitingPhase 3
New PET scan for pancreatic cancer staging
This study tests a new type of PET scan that uses a radioactive tracer called FAPI-74 to find cancer spread in people with pancreatic cancer. The goal is to see if this scan can help doctors better plan treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04858334RecruitingPhase 2
Olaparib after pancreatic cancer surgery for BRCA or PALB2 mutations
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
Bryn Mawr, PennsylvaniaAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07554560Recruiting
Nutrition Support for Pancreatic Cancer Patients
This study tests a nutrition intervention for people with pancreatic cancer who are having trouble eating or absorbing nutrients. The goal is to help patients maintain strength and improve their quality of life during cancer treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04172532RecruitingPhase 1/Phase 2
New targeted drug with radiation for locally advanced pancreatic cancer
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06958328RecruitingPhase 3
Higher dose radiation for locally advanced pancreatic cancer
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Chadds Ford, PennsylvaniaAges 18 years+ - NCT06747845RecruitingPhase 2
Maintenance therapy for stable metastatic pancreatic cancer
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07409272RecruitingPhase 3
Study of setidegrasib with chemo for pancreatic cancer
This trial tests a new drug called setidegrasib, given with two types of chemotherapy (mFOLFIRINOX or NALIRIFOX), for people whose pancreatic cancer has spread and has a specific genetic change called KRAS G12D. The goal is to see if adding setidegrasib helps control the cancer better than chemo alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06073431Recruiting
Study on weight loss types in advanced cancer
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Wilkes-Barre, PennsylvaniaAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Broomall, PennsylvaniaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05482893RecruitingPhase 1/Phase 2
Spevatamig for advanced stomach, pancreas, or bile duct cancer
This trial tests a new drug called Spevatamig (PT886), alone or with different chemotherapy and/or immunotherapy combinations, for people with certain advanced stomach, pancreatic, or bile duct cancers. The goal is to see if it shrinks tumors and is safe.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07199764RecruitingPhase 2
Maintenance therapy using combination immunotherapy for pancreatic cancer
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06850623RecruitingPhase 2
Sound wave therapy plus chemo for advanced pancreatic cancer
This trial tests a new treatment that uses sound waves to help chemotherapy reach pancreatic tumors more effectively. It is for people with locally advanced pancreatic cancer that cannot be removed with surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT00912717Recruiting
Study of pancreas cancer risk in families and environment
This study looks at factors in the family and the environment that may be linked to pancreatic cancer. It includes people with pancreatic cancer and several types of pancreas-related conditions, as well as some healthy volunteers, and may help researchers understand who is at higher risk.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06984562Recruiting
Adaptive radiation therapy for advanced pancreatic cancer
This trial tests a new way of giving radiation therapy that adapts to changes in your cancer over time. It is for people with pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+
Pancreatic Adenocarcinoma trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting pancreatic adenocarcinoma studies listed above.
- University of Pennsylvania · 10 studies
- Thomas Jefferson University Hospital · 5 studies
- Allegheny General Hospital · 3 studies
- Fox Chase Cancer Center · 3 studies
- UPMC Hillman Cancer Center · 3 studies
- Christiana Care Health System-Concord Health Center · 2 studies
- Geisinger Medical Center · 2 studies
- Geisinger Medical Oncology-Lewisburg · 2 studies
What taking part in a pancreatic adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Pancreatic Adenocarcinoma trials in other states
Common questions
- Are there pancreatic adenocarcinoma clinical trials in Pennsylvania?
- Yes. We're currently tracking 40 recruiting pancreatic adenocarcinoma studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a pancreatic adenocarcinoma study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New pancreatic adenocarcinoma studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.